Siemens and BioNTech expand their collaboration for global vaccine production
• Siemens supplies the latest automation and digitalization technology for the
production of Covid-19 vaccines
• Joint creation of a vaccine production facility in Singapore.
German biotechnology company BioNTech SE, based in Mainz, and Siemens intend
to expand their strategic cooperation. The companies plan to intensify their
collaboration for the rapid expansion and creation of production capacity for the
Covid-19 vaccine. BioNTech has expressed its aim of establishing new production
sites for Covid-19 vaccine production worldwide based on the Marburg plant and its
technology, starting with a production facility in Singapore. In Marburg, BioNTech
has converted an existing plant into a vaccine production facility with support from
Siemens in just five months.
Within this cooperation, Siemens will provide the latest automation and digitalization technologies for BioNTech production sites, such as design, simulation, and engineering software as well as process control technology.
German biotechnology company BioNTech SE and Siemens intend to expand their strategic cooperation. The companies plan to intensify their collaboration for the rapid expansion and creation“Siemens and BioNTech have worked together successfully for years. BioNTech
was one of the first companies together with Pfizer to bring a new mRNA vaccine to
market. Our technologies and long-standing expertise have helped them to convert
their production facility in just five months rather than a year. We now want to
transfer this success to other production sites in order to make Covid-19 vaccines
available as quickly as possible worldwide,” says Cedrik Neike, Member of the
Board of Siemens AG and CEO Digital Industries.
Twitter:
http://www.twitter.com/siemens_press and http://www.twitter.com/SiemensIndustry
Blog: https://ingenuity.siemens.com
